АТОРВАСТАТИН У БОЛЬНЫХ С ОСТРОЙ И ХРОНИЧЕСКОЙ ФОРМОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА
https://doi.org/10.15829/1560-4071-2015-11-98-103
Аннотация
В обзоре представлены данные клинических исследований, в которых продемонстрирована возможность эффективной терапии статинами острой и хронической форм ишемической болезни сердца. Анализируется применение максимальных доз аторвастатина, его раннее назначение, в первые 24-96 ч после острого сердечно-сосудистого события и при подготовке к реваскуляризации с целью снижения риска развития осложнений, смертности и улучшения прогноза. Рассматривается положительное действие аторвастатина, обусловленное не только гиполипидемическими свойствами, но и рядом плейотропных эффектов. Приведен анализ данных о частоте и тяжести побочных реакций у пациентов, получающих статины.
Об авторах
В. Э. Олейников
ФГБОУ ВПО Пензенский государственный университет, медицинский институт, Пенза, Россия
Россия
д. м.н., профессор, зав. кафедрой терапии
Россия
д. м.н., профессор, зав. кафедрой терапии
А. А. Хромова
ФГБОУ ВПО Пензенский государственный университет, медицинский институт, Пенза, Россия
Россия
ассистент кафедры терапии
Россия
ассистент кафедры терапии
Л. И. Гусаковская
ФГБОУ ВПО Пензенский государственный университет, медицинский институт, Пенза, Россия
Россия
доцент кафедры терапии
Россия
доцент кафедры терапии
Н. В. Сергацкая
ФГБОУ ВПО Пензенский государственный университет, медицинский институт, Пенза, Россия
Россия
ст. преподаватель кафедры терапии
Россия
ст. преподаватель кафедры терапии
Е. М. Романовская
ФГБОУ ВПО Пензенский государственный университет, медицинский институт, Пенза, Россия
Россия
Россия
ассистент кафедры терапии
Список литературы
1. Roger V, Go A, Lloyd-Jones D, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: 2-220.
2. Vale N, Nordmann AJ, Schwartz GG, et al. Statins for acute coronary syndrome. Cochrane Database of Systematic Reviews. Issue 9. John Wiley & Sons, Ltd; 2014.
3. Aronov DM, Bubnova MG. Pleiotropic effects of statins at the present stage of its research (focus on atorvastatin). CardioSomatika 2012; 3: 3-5. Russian (Аронов Д. М., Бубнова М. Г. Плейотропные эффекты статинов на современном этапе их изучения (фокус на аторвастатин). CardioСоматика 2012; 3: 3-5).
4. Athyros V, Moses E, Papageorgiou A, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. AJKD 2004; 43: 589-99.
5. Pajl K, Kennedi L, Shostak N. Diagnosis and treatment in rheumatology. Problematic approach. ЕOTAR-Media 2011; 368s. Russian (Пайл К., Кеннеди Л., Шостак Н. Диагностика и лечение в ревматологии. Проблемный подход. ГЭОТАР-Медиа 2011; 368с.).
6. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: 69-171.
7. Kearney P, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a etaanalysis. Lancet 2008; 371: 117-25.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
9. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 2007; 14 (20): 1-113.
10. Conclusion Expert Society of Cardiology of the Russian Federation, Russian National Society of Atherosclerosis, Russian Society cardiosomatic rehabilitation and secondary prevention to optimize statin therapy in clinical practice. Rational Pharmacother Card 2011; 7(1): 107-109. Russian Заключение экспертов ВНОК, НОА, РОСОКР по оптимизации терапии статинами в клинической практике). РФК 2011; 7(1): 107-9.
11. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiology 2007; 49(12): 1272-8.
12. Koren MJ, Hunninghake DB. Clinical Outcomes in Managed-Care Patients With Coronary Heart Disease Treated Aggressively in Lipid-Lowering Disease Management Clinics The ALLIANCE Study. J Am Coll Сardiology 2004; 44(9): 1772-9.
13. National Institute for Health and Care Exellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. BMJ 2014; 349-56.
14. Spencer F, Allegrone J, Goldberg R, et al. Association of statin therapy with outcomes of acute coronary syndromes: The Grace Study. Ann Intern Med 2004; 140: 857-66.
15. Schwartz G, Olsson A, Ezekowitz M, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL Study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
16. Pedersen TR, Cater NB, Faergeman O, et al. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J Cardiology 2010; 106: 354-9.
17. Giraldez RR, Giugliano RP, Mohanavelu S, et al. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiology 2008; 52: 914-20.
18. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiology 2013; 61(4): 78-140.
19. Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Atherosclerosis 2007; 191(1): 135-46.
20. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiology 2008; 103(5): 398-406.
21. Ryan P, George A, Sanjay K. Statins in Acute Coronary Syndromes: Do the Guideline Recommendations Match the Evidence? J Am Coll of Cardiology 2009; 54(15); 1425-33.
22. Papageorgiou N, Tousoulis D, Antoniades C, et al. The impact of statin administration in acute coronary syndromes. Hellenic J Cardiology 2010; 51: 250-61.
23. Greenwood J, Steinman L, Zamvil S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nature Publishing Group 2006; 6: 358-70.
24. Muller WA. The regulation of transendothelial migration: new knowledge and new questions. Cardiovasc Res 2015; 107: 310-20.
25. Dupuis J, Tardif J, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-33.
26. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33(13):1635-701.
27. Schoenhagen P, Tuzcu ME, Apperson-Hansen C, et al. Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy. Serial Intravascular Ultrasound Observations From the Reversal of Atherosclerosis With Aggressive Lipid Lowering Therapy (REVERSAL) Trial. Circulation 2006; 113: 2826-34.
28. Pignatelli P, Sanguigni V, Lenti L, et al. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. J Thromb Haemost 2007; 5(6):1170-8.
29. Otsuka F, Hibi K, Kusama I, et al. Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction. Atherosclerosis 2010; 213: 505-11.
30. Ughi GJ, Adriaenssens T, Sinnaeve P, et al. Automated tissue characterization of in vivo atherosclerotic plaques by intravascular optical coherence tomography images. Biomed Opt Exp. 2013; 4(7): 1014-30.
31. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004; 110: 1061-8.
32. Hausenloy D, Yellon D. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007; 12: 217-34.
33. Zhang L, Cheng L, Wang Q, et al. Atorvastatin protects cardiomyocytes from oxidative stress by inhibiting LOX-1 expression and cardiomyocyte apoptosis. Acta Biochim Biophys Sin (Shanghai) 2015; 47(3): 174-82.
34. Lemoine S, Zhu L, Legallois D, et al. Atorvastatin-induced cardioprotection of human myocardium is mediated by the inhibition of mitochondrial permeability transition pore opening via tumor necrosis factor-a and Janus kinase/signal transducers and activators of transcription pathway. Anesthesiology 2013; 118(6): 1373-84.
35. Cohen J, Brinton E, Jacobson T, et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidology 2012; 6: 208-15.
36. Bitzur R, Cohen H, Kamari Y. Intolerance to Statins: Mechanisms and Management. Diabetes Care 2013; 36(Suppl 2): 325-30.
37. Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiology 2006; 97 (1): 61-7.
38. Hoffman K, Kraus C, Beatrice A, et al. A Survey of the FDA’s AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class. PLOS ONE 2012; 7: 1-6.
39. Bays H, Cohen D, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidology 2014; 8: 47-57.
40. Gillett С, Norrell А. Considerations for Safe Use of Statins: Liver Enzyme Abnormalities and Muscle Toxicity. Am Fam Physician. 2011; 83(6): 711-6.
41. 41. Simon T, King L, Zheng H, et al. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatology 2015; 62(1):18-23.
42. Calderon R, Cubeddu L, Goldberg R, et al. Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: A Therapeutic Dilemma. Mayo Clin Proc 2010; 85(4): 349-56.
43. Zipes DP, Zvaifler NJ, Glassock RJ, et al. Rosuvastatin: An Independent Analysis of Risks and Benefits. Medscape Gen Med. 2006; 8(2): 73-93.
44. Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
45. Preiss D, Seshasai S, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305 (24): 2556-64.
46. Henriksbo B, Lau T, Cavallari J, et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 2014; 63: 3742-7.
47. Yan Y, Jiang W, Spinetti T, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013; 38: 1154-63.
48. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. US FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. (15 August, 2013).
49. Jacobson T. The NLA Task Force on Statin Safety — 2014. J. Clinical Lipidology 2014; 8: 1-4.
50. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
Рецензия
Для цитирования:
Олейников В.Э., Хромова А.А., Гусаковская Л.И., Сергацкая Н.В., Романовская Е.М. АТОРВАСТАТИН У БОЛЬНЫХ С ОСТРОЙ И ХРОНИЧЕСКОЙ ФОРМОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА. Российский кардиологический журнал. 2015;(11):98-103. https://doi.org/10.15829/1560-4071-2015-11-98-103
For citation:
Oleynikov V.E., Khromova A.A., Gusakovskaya L.I., Sergatskaya N.V., Romanovskaya E.M. ATORVASTATIN IN ACUTE AND CHRONIC KINDS OF ISCHEMIC HEART DISEASE. Russian Journal of Cardiology. 2015;(11):98-103. (In Russ.) https://doi.org/10.15829/1560-4071-2015-11-98-103
Просмотров:
665
Послать статью по эл. почте 